the reaction / frustration is all understandable when you look...

the reaction / frustration is all understandable when you look at the stock price - the loss time and money.
he simply put it . one step back 2 forward.
reading the cc again , he was transparent which was good and he had to be or the company is done.

simply put , had we stayed on the old path :

- potential 2 years to finish enrollment ( with current issues of driveline + invasive procedure I doubt we can finish enrollment in  2 years )

- 1 year follow up period after enrollment. which makes it 2016-2017-2018. so we should expect fda approval early 2019. that is for cp1.

we would still need lots of financing and probably up to $90-100m to continue on that plan. big dilution fears.


the new path

- 2016 set up the new strategy and approval to start the new trial + financing in q3.
- 2017 , start of trial + follow up . + cp2 ( which he mentions we will be able to commercialize )
-2018 approval.

cp1 is a stop gap. cp2 is the real deal.

Commenting on the appointment, Paul Buckman, the Company’s Lead Independent Director said, “The Board of Directors is pleased that someone as qualified as John will be leading the company. John has the leadership skills and proven track-record that make him an excellent fit for Sunshine Heart’s growth and strategic plans."

strategic plans = teaming with a big pharma which will help $$$ and help with the development of cp2.

if this was going down , there would have been a big pump and dump and the big players would have gone out before any warning signs.

a year ago we were 10x this level. last quarter 4x this level. no reason why we shouldnt have similar moves to the upside.

nothing will happen overnight. but 1 year from now lots of things could and should happen.

my main concern and worry is for us to get the financing out of the way and throw away any split scenarios.

dilution : no1 wants that , but were small holders . do you reckon major shareholders would accept major dilution? not a chance.



the bad :

many have inside information as shown by the shorts.
lack of actual transperancy by previous management.
split risks down the line if price doesnt go back to $1

conclusion :

we have a good product with rough edges and a big market.
make your product great instead of good and minimize the flaws and own the market.

personal view :

if strategy is executed well  , we will be sold upon approval of cp2.
price ( 300-900m) $10-$30